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Abstract 
Background. Anal cancer is a relatively rare GI malignancy with some controversy regarding 
several aspects of therapy including chemotherapy agents, radiation dose, and timing.  
Methods.  A retrospective review of all patients treated for anal cancer from 1986 to 2006 was 
conducted at the University of Kansas Medical Center (KUMC) Department of Radiation 
Oncology.   
Results. This report details 33 patients treated with external beam radiation.  Most patients 
(88%) had chemotherapy consisting of 5-FU and either mitomycin (42%) or cisplatin (45%), 
concurrently (88%) or sequentially (3%) with radiation.  Surgery was performed prior to the 
radiation in 12 (36%) patients, 2 (6%) with an abdominoperineal resection, and 10 (30%) with 
local excision.  Acute grade 3-4 morbidity was seen in 22 (67%) patients and late grade 3-4 
morbidity was present in 2 (6%) patients. Two patients had progression of disease and 4 patients 
had disease recurrence, with local recurrence in 2 patients and distant recurrence in 2 patients; 29 
patients (88%) had no evidence of disease at last follow-up. At a median follow-up of 4.6 years, 
overall survival was 74% and disease free survival was 79%.   
Conclusion. Treatment factors including radiation dose, treatment time, and chemotherapy 
agents were not found to influence either overall survival or local control. KJM 2007; 1(2):27-37 
 
 
Introduction 
Although relatively rare, an estimated 
4600 new cases of anal cancer will be 
diagnosed in 2006.1  The treatment option 
for these patients at one time would have 
consisted of an abdominoperineal resection 
(APR) entailing total anal sphincter sacrifice 
and a permanent diverting colostomy.  
Today, treatment options include sphincter-
sparing approaches using radiation and 
chemotherapy without compromising local 
control or survival.2  While local control is 
good, there are still many issues in the 
treatment of this disease that are unsettled. 
Chemotherapy has not shown a survival 
advantage when compared to radiation alone 
although it is associated with an improved 
local control rate and is considered  standard  
 
 
of care.  The chemotherapy used in the 
initial chemoradiation trials was mitomycin 
and 5-FU that are associated with significant 
treatment morbidity.3-5  To reduce the side 
effect profile of combination therapy, some 
have investigated if cisplatin chemotherapy 
could prove to be equivocal or even superior 
to mitomycin. Good clinical outcomes with 
cisplatin chemotherapy have been shown in 
several retrospective reviews6-8 and the 
preliminary reports of a phase III trial9, but 
more information is needed before cisplatin 
can be considered standard of care.   
Another unclear aspect of anal cancer 
treatment is the ideal radiation dosage and 
schedule. While some reviews10 have found 
30 gray (Gy) to be adequate for tumor 
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control, others11,12 have not found this to be 
true.  Higher radiation doses have been 
associated with a greater degree of treatment 
complications13-14 and it is not established 
what dose best balances toxicity and tumor 
control. 
A retrospective review of the anal cancer 
patients treated at the University of Kansas 
Medical Center (KUMC) was conducted to 
provide more information regarding 
treatment outcomes and the role of 
chemotherapy agents, radiation dose, and 
treatment morbidity.  
 
Methods 
Treatment information was obtained by 
retrospective review of the hospital and 
radiation oncology charts for all anal cancer 
patients treated at KUMC from 1986 to 
2006.  Prior to review, approval for the 
study was granted by the KUMC Human 
Subjects Committee.  Thirty-four patients 
were available for analysis; one patient had 
metastatic disease at presentation and was 
not included in this analysis. Of the 33 
patients included in the analysis, there were 
15 males and 18 females, with a median age 
of 57 years at the time of radiation.  Six 
(18%) patients were known to have HPV 
and 3 (9%) patients had HIV.   
Patient characteristics are summarized in 
Table 1. Most of the patients were early 
stage, with one Tis (3%), six (18%) T1, 15 
(45%) T2, five (15%) T3, and six (18%) T4 
tumors. (See Table 2 for staging 
characteristics.)  Twenty-one (64%) patients 
were lymph-node negative with 12 patients 
(36%) having positive lymph nodes.  
Treatment involved external beam 
radiation for all 33 patients (see below for 
dose and timing of radiation), chemotherapy 
for 29 (88%) patients, and primary surgery 
followed by adjuvant radiation in 12 (36%) 
patients, with nine (27%) having adjuvant 
chemoradiotherapy.  
 
Table 1.  Patient characteristics. 
Median age 57 years 
Age range 34-80 years 
Male 15 (45%) 
Female  18 (55%) 
HIV positive 3 (9%) 
HPV positive 6 (18%) 
Tumor location  
Anorectal junction 6 (18%) 
Anal canal 20 (60%) 
Cloacogenic zone 7 (21%) 
Tumor histology  
SCC in situ 1 (3%) 
Basaloid 2 (6%) 
SCC keratinizing 30 (90%) 
 
Table 2.  Staging characteristics. 
T1 6 (18%) 
T2 15 (45%) 
T3 5 (15%) 
T4 6 (18%) 
Tis 1 (3%) 
N1 5 (15%) 
N2 3 (9%) 
N3 4 (12%) 
N0 21 (64%) 
 
All patients were treated exclusively 
with  external  beam  radiation;   no  patients 
had brachytherapy as a component of their 
treatments. The initial treatment plan was a 
whole pelvis plan that consisted of two 
lateral and two anterior-posterior radiation 
beams (see Figure 1). The purpose of the 
whole pelvis field is to supply radiation to 
the cancer and the surrounding areas that are 
at risk for microscopic tumor involvement. 
The median radiation dose for the initial 
treatment was 45 Gy (range 30.6 Gy to 50.4 
Gy).  
Four radiation beams are used for the 
pelvic field to reduce the radiation dose to 
the normal tissues such as the bladder, 
rectum, and  bowel.    The initial pelvic field 
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Figure 1.  Lateral and anterior-posterior field images. 
 
was followed by a reduced-volume boost 
treatment in 21 (64%) patients to deliver 
further radiation to the target while keeping 
the radiation dose to the normal structures as 
low as possible. The boost treatment 
targeted the areas of gross disease without 
targeting areas of possible microscopic 
involvement; the theory being that the lower 
dose used in the larger pelvic field is 
adequate for microscopic disease while the 
gross tumor requires more radiation.  
The median boost dose was 16.2 Gy 
(range 4 Gy to 30.6 Gy). The median total 
dose, excluding one noncompliant patient, 
was 54.9 Gy with a range of 45 to 66.6 Gy. 
The median number of total fractions was 31 
with a range of 25 to 49 fractions. 
Treatments were delivered daily (Monday 
through Friday). Radiation treatments were 
scheduled consecutively without break 
unless patient toxicity required a break for 
healing.  Any break in the radiation will 
prolong the overall treatment time. The 
median treatment time was 56 days with a 
range of 32 days to 149 days.  Table 3 
exhibits treatment characteristics. 
The type of surgical resection was an 
APR with diverting colostomy in two (6%) 
patients, and local excision in 10 (30%) 
patients.   The two patients treated with an 
initial    APR    had    subsequent    treatment  
 
 
Table 3.  Treatment characteristics. 
Primary treatment  
Radiation 33 (100%) 
Surgery 12 (37%) 
Chemotherapy 29 (88%) 
Surgery + Radiation 3 (9%) 
Surgery + Radiation +  
Chemotherapy 
9 (27%) 
Chemotherapy  
5-FU + Mitomycin 14 
5-FU + Cisplat 15 
Cycle (median) 2 
Cycle (range) 0-3 
Concurrent 28 
Sequential 1 
Radiation  
Dose (median) 54 Gy 
Dose (range) 12.0-66.6 Gy 
Fractions (median) 31 
Fractions (range) 7-49 
Patients receiving boost 
treatment 
20 
Boost dose (median) 16.2 Gy 
 
secondary to advanced disease found at the 
time of surgery (T4N0 and T2N3).   Chemo- 
therapy consisted of 5-FU and mitomycin in 
14 (42%) patients, 5-FU and cisplatin in 15 
(45%) patients. Twenty-nine (88%) 
chemotherapy  regiments   were   concurrent 
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with the radiation with one patient (3%) 
receiving sequential 5-FU and cisplatin prior 
to the radiation. One (3%) patient had one 
cycle of chemotherapy, 16 (48%) patients 
had two cycles, and seven (21%) patients 
had three cycles.  Information on the number 
of chemotherapy cycles was not available 
for five (15%) patients. 
One patient was noncompliant with 
radiation therapy and discontinued treatment 
after seven fractions (12.6 Gy) and two 
rounds of chemotherapy (5-FU, cisplatin). 
One patient had a reduced boost dose from 
an initially-prescribed 10.8 Gy in six 
fractions to a received 4 Gy in two fractions 
secondary to skin morbidity. The rest of the 
patients received the prescribed doses.   
Follow-up data were obtained from the 
hospital and radiation therapy charts and the 
KUMC tumor registry that collects 
information on cancer patients annually. 
Patients were seen in follow-up typically 
every three months after the completion of 
treatment for two years, then every six 
months for five years and annually 
thereafter.  
Statistical analysis was performed with 
SPSS for Windows (Release 12.0, SPSS Inc, 
Chicago, IL). Categorical variables were 
summarized by frequencies and percentages, 
and quantitative variables were summarized 
by medians and ranges. Quantitative 
variables were compared across groups 
using the Kruskal-Wallis test. The Wilcoxon 
rank sum test was used to perform pairwise 
comparisons on quantitative variables that 
were globally different among groups. The 
Fisher’s exact test was used to compare 
categorical variables among groups.  
The duration of follow-up was calculated 
from the time of diagnosis until the date of 
death or last known follow-up. Univariate 
analysis of time to death (overall or disease-
specific) was analyzed by the Kaplan-Meier 
survival analysis. Categorical variables were 
compared by the log-rank test and 
continuous variables by Cox proportional 
hazards analysis. Probability values of 
p<0.05 were considered to be statistically 
significant. No corrections for multiple 
comparisons were made. 
 
Results 
At last follow-up, 21 (64%) of the 33 
patients were alive.  At a median follow-up 
of 4.6 years (range, 0.1 years to 17.6 years), 
74% of patients were alive. Twenty-nine 
patients (88%) were free of disease at last 
follow-up with 2 (6%) patients alive but 
with evidence of disease. At the median 
follow-up time, 79% of patients were free of 
disease.  
Two patients (6%) had persistent disease 
after treatment; these patients never 
achieved a disease-free state.  Four patients 
had disease recurrence.  The median time to 
recurrence was 1.9 years with a range of 0.6 
years to 2.2 years.  No recurrences were 
seen after 2.2 years. Two of the four 
recurrences were distant sites occurring in 
one patient with lung and another patient 
with both lung and liver metastases. 
Treatment for recurrences consisted of a 
colostomy in two patients and a pulmonary 
resection for one patient. Local control was 
established in 29 (88%) patients (see Tables 
4 and 5).  
 
Table 4.  Summary data for patients with 
persistent disease or recurrence. 
Persistent disease 2 
Recurrences 4 
Persistent disease or recurrence  6 
Time to recurrence (median) 1.9 years 
Time to recurrence (range) 0.55 to 
2.2 years 
Recurrence Site  
Local 4 
Distant 2 
Distant Sites  
Lung  2 
Liver 1 
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Table 5.  Patients with persistent disease or recurrence. 
Patient Recurrence 
type 
Time to 
recurrence 
(years) 
CTX Dose 
(Gy) 
Treatment 
time 
(days) 
HIV 
status 
Age T 
stage 
N 
stage 
Gender Primary 
Surgery 
Salvage 
surgery 
1 Persistent * 5-FU, 
MMC 
45 39 Negative 76 2 0 Female No No 
2 Local 2.16 5-FU, 
Cisplatin 
49 52 Negative 69 3 1 Female No Colostomy 
3 Persistent * 5-FU, 
Cisplatin 
65 149 Negative 38 4 0 Female Local 
excision 
No 
4 Local 0.55 None 66.6 71 Positive 35 2 2 Male Local 
excision 
Colostomy 
5 Distant 1.63 5-FU, 
MMC 
45 82 Positive 43 2 0 Male No No 
6 Distant 2.16 5-FU, 
Cisplatin 
53.8 62 Negative 57 1 0 Female No Pulmonary 
resection 
*Patient was never disease free. 
 
 
 
Figure 2.  Treatment morbidity. 
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A colostomy was performed prior to 
radiation in two (6%) patients and after 
definitive treatment in three of the remaining 
31 patients (9.6%).  Two (6%) of these 
patients had a colostomy for disease 
recurrence and one (3%) for late radiation 
side effects. The time-to-colostomy for the 
two patients with colostomy for disease 
recurrence were 0.6 and 2.2 years and 5.4 
years for the patient with colostomy for 
treatment morbidity. The median colostomy-
free survival was 5.1 years for the 31 
patients not having a colostomy prior to 
definitive treatment and 4.6 years overall.  
Treatment morbidity was graded by the 
Radiation Therapy Oncology Group 
(RTOG) radiation morbidity scoring criteria.  
Per the RTOG scale, treatment toxicities are 
divided into acute (occurring during 
treatment or within 6 months of the end of 
radiation therapy) or late (occurring after 6 
months of the completion of radiation 
therapy).  Toxicity  is  graded  for both acute  
and late toxicities on a scale of 1 (most 
benign) to 5 (toxicity resulting in patient 
demise).  All patients had some form of 
acute morbidity.  Eleven (39%) patients had 
acute grade 1-2 morbidity and 22 (66%) 
patients had acute grade 3-4 morbidity.  No 
patients died during treatment (no grade 5 
toxicity). Twenty (60%) patients had no late 
treatment toxicity, 11 (33%) patients had 
grade 1-2 late morbidity, and two (6%) 
patients had grade 3-4 late morbidity. 
For the 10 patients who had surgical 
excision prior to radiation, 30% had grade 1-
2 morbidity and 10% had grade 3-4 
morbidity. This was not statistically 
different from patients who did not have 
pre-radiation surgery. The acute toxicities 
for the two chemotherapy regimens were 
different (p=0.017, Fishers exact test), with 
the 5-FU and cisplatin regimen having over 
twice as many (13 versus 6) grade 3-4 acute 
side effects compared to 5-FU and 
mitomycin (see Figure 2 and Table 6). 
 
 
Table 6. Comparison of chemotherapy agents. 
 
Patients with HIV had worse disease-
free survival than patients without HIV 
(p=0.0021, log-rank test). Of the 3 HIV 
positive patients, two (66%) had a local 
recurrence at 0.6 and 1.6 years.  None of the 
six HPV patients had a disease recurrence 
with a median follow-up of 6.8 years.  Side 
effects for the HPV patients were similar to 
that of the non-HPV population with two 
(33%) having grade 1-2 acute morbidity, 
four (66%) having grade 3-4 acute 
morbidity, and two (33%) having grade 1-2 
late morbidity.  None of the HPV positive 
patients had a grade 3-4 late morbidity.  
The total dose received did not influence 
local control or overall survival.  Two (13%) 
of 16 patients that received more than 55 Gy 
had a recurrence (both local) and four (24%) 
of 17 patients that received less than 55 Gy 
had a recurrence (two local and two distant) 
(p=0.48).  Overall survival at the median 
follow-up time was approximately 70% for 
patients that received greater than or less 
than 55 Gy (p = 0.61). There was a relation 
between age and total dose, with a median 
age of 46 years for patients that received 
more than 55 Gy and a median age of 66 
years for patients that received less than 55 
Gy (p = 0.011).  
Chemotherapy Number G3-4 Acute G1-2 Late G3-4 Late Recurrences 
5-FU + 
mitomycin 
14 6 6 1 2 
5-FU + cisplatin 15 13 6 0 3 
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Acute and late morbidity was not related 
to treatment dose.  Twelve of 16 (75%) 
patients receiving doses greater than 55 Gy 
had acute grade 3 or 4 morbidity compared 
to 10 of 17 (59%) patients receiving below 
55 Gy. Eight of the 14 patients with late 
morbidity occurred in the above 55 Gy 
treatments, with 6 occurring in the lower 
treatment dose (see Table 7).   
No survival difference was seen in the 
patients who received 5-FU and mitomycin 
versus those receiving 5-FU and cisplatin. 
For the 12 patients who had a primary 
surgical treatment, there was one patient 
with persistent disease and one patient with 
a local recurrence.  Patients who had surgery 
prior to radiation had a median overall 
survival of 3.3 years and a disease free 
survival (DFS) of 3.3 years compared to a 
median overall survival of 5.2 years and 
median DFS of 4.9 years for patients 
without primary surgery.  
Elapsed treatment time did not influence 
local control or overall survival with four 
(20%) recurrences in 20 patients that 
required more than 55 days to complete their 
radiation therapy and two (15%) recurrences  
in 13 patients that finished treatment in less 
than 55 days.  There were no differences in 
treatment morbidity between patients who 
finished treatment in more compared to less 
than 55 days.  
 
Table 7. Treatment morbidity and total dose. 
 
Discussion 
Local control of 88% of the patients and 
the survival outcomes were consistent with 
some of the ranges reported in the literature. 
Local control rates reported in the literature 
ranged from 39% to 61% in the prospective 
randomized trials3-5 and 60% to 89% for 
retrospective reviews13-25. In some recent 
reports, Das et al.25 described 3-year local 
control rates of 81% and overall survival of 
84%, the University of Florida23 reported an 
overall local control rate of 85% with 53% 
of the reviewed patients receiving 
chemotherapy, and Ferrigno et al.13 found a 
local control rate of 79% using chemo-
radiotherapy with 5-FU and mitomycin.  An 
interesting aspect of the current data was 
that there was no recurrence past 2.2 years.  
If this finding is demonstrated in other 
reviews, it may be possible that future anal 
cancer trials can report findings with 
confidence at the 3-year mark (see Figures 3 
and 4).  
 
 
The results of this retrospective review 
did not yield any guidelines for some of the 
unanswered questions regarding the 
treatment for anal cancer. No difference was 
found between patients treated with the 5-
FU and mitomycin regimen compared to 5-
FU and cisplatin. The side effect profile for 
the two chemotherapy regimens was not 
different for late toxicities, but there was a 
greater number of acute grade 3-4 
complications (13 versus 6) with the 5-FU 
and cisplatin than with 5-FU and mitomycin. 
Several authors6-8 have reported the success 
of 5-FU and cisplatin, although the 
preliminary report9 of the randomized trial 
comparing the two chemotherapy regiments 
did not show a significant difference in 
overall survival.  
There may be select patients not 
requiring any chemotherapy.  A report from 
the University of Florida does not 
recommend  chemotherapy  for  T1  or  early 
Dose # of Patients G1-2 Acute G3-4 Acute G1-2 Late G3-4 Late 
< 55 Gy 17 7 10 5 1 
> 55 Gy 16 6 12 7 1 
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Figure 3.  Kaplan-Meier overall survival curve.  The marks indicate censored patients. 
 
 
Figure 4.   Kaplan-Meier disease free survival curve.  The marks indicate censored patients.
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T2 malignancies.23  Four patients in this 
report did not receive any chemotherapy.  
These patients had similar local control and 
overall survival to the patients who did 
receive chemotherapy.  Again, the small 
number of treated patients makes it hard to 
detect differences and most patients not 
receiving chemotherapy had early-stage 
cancers. Three of the four patients not 
receiving chemotherapy had T1N0 cancers 
and the fourth patient had a T2N2 cancer.  
This last patient was an HIV positive male 
with multiple co-morbidities contra-
indicating chemotherapy.  The patient had 
an early recurrence requiring colostomy 
after 0.6 years.  
Another controversy in the treatment of 
anal cancer is radiation dose. Hu et al.12 
concluded that a certain subset of patients 
(excisional biopsy in combination with 
chemotherapy) may only require 30 Gy for 
local control. Several other authors13-14 
found a lower dose to be an adverse 
prognostic factor. Constantinou et al.10 
found doses below 54 Gy to have inferior 
local control (61%) versus higher doses 
(77%). Ferrigno et al.13 also reported that 
higher doses had improved local control, 
with local control rates of 87% and 34% for 
patients above and below 50 Gy.   
The present study found no statistically 
significant difference in patients treated to 
higher doses. However, there was a 
statistically significant difference in the age 
of patients treated to higher doses.  Elderly 
patients were more likely to be prescribed 
lower radiation doses, and it was possible 
that this masked the benefits for higher 
doses of radiation. 
Side effects were seen in the majority of 
patients.  Only one patient required a 
colostomy for late radiation complications 
and there were no statistically significant 
relations between side effect profile and 
treatment dose, treatment duration, or 
chemotherapy regiment. The overall late 
grade 3-4 morbidity was 6% and grade 1-2 
late toxicity was 33%. This was slightly 
lower than the late toxicity range of 8-19% 
found by others.18   
Allal et al.11 reported an association 
between late toxicity and initial (pre-boost) 
radiation dose with large-volume treatments 
above 39.6 Gy having a 23% incidence of 
late complications versus 7% for whole 
pelvis treatments less than 39.6 Gy. Age and 
previous excision were risk factors for 
treatment complications.  
In the present study, no association 
between late toxicity and previous excision, 
radiation dose, or age was found.  A 
statistically significant difference, however, 
was found in the median dose between 
patients older and younger than 55. The 
selection bias for treating older patients to 
less radiation could account for the lack of 
relationship between late toxicity and age or 
radiation dose.  
A small subset of the treated patients had 
HIV or HPV.  While HPV did not appear to 
have a worse prognosis, there was a 
disproportionate number of failures in the 
HIV positive population. The HIV patients 
did not receive lower doses of radiation (two 
of the three patients received higher than the 
median dose) and two of the three had 
concurrent chemotherapy. The one HIV 
patient that did not have a recurrence had an 
aggressive treatment course consisting of 
local surgical excision followed by 5-FU, 
mitomycin, and 59.4 Gy of radiation. 
Edelman et al.26 retrospectively reviewed 17 
HIV positive patients treated with radiation 
and chemotherapy (5-FU and mitomycin or 
cisplatin) and found an actuarial 18-month 
survival of 67%.  Others have found similar 
survival rates.27-28 Thus, HIV positive 
patients have worse outcomes than the 
general population which is influenced 
largely by HIV-related infections.   
There are several limitations to the 
information in this report. First, the 
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information is retrospective.  Although there 
is a long-term follow-up, it is possible that 
some recurrences were missed.  Second, all 
patients were from a single institution and 
regional differences in practice and patient 
characteristics may bias the generalizability 
of these data. Third, the small number of 
patients may be under-powered to detect 
treatment differences in terms of radiation 
dose, treatment duration, and the difference 
chemotherapy regiments. Overall, despite 
these possible limitations, the information is 
valuable in adding to the literature base 
about the treatment outcomes for anal 
cancer, especially in showing that smaller 
institutions can achieve results comparable 
to larger volume centers. 
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